BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

TB Alliance declares potential of two novel TB drugs

October 12, 2017 | News

Both compounds have proceeded through early preclinical development and were granted "Investigative New Drug" status by the U.S. Food and Drug Administration.



TB Alliance recently announced that TBA-7371 and sutezolid entered phase 1 clinical trials. Both compounds have proceeded through early preclinical development and were granted "Investigative New Drug" status by the U.S. Food and Drug Administration. The phase 1 clinical trials are presently ongoing.

TBA-7371 is an antimicrobial compound developed by TB Alliance in collaboration with AstraZeneca. Sutezolid on the other hand belongs to a class of drugs that has already shown evidence of clinical activity against TB but the associated toxicity can be problematic.

In March 2017, TB Alliance and the Medicines Patent Pool announced a sublicensing agreement for the development and commercialization of sutezolid for the treatment of TB.

We still have a way to go before we arrive at a universal cure for this disease, but we have building blocks coming through the research pipeline that show us we can get there.